Key result
Atorvastatin daily for 8 weeks did not change blood eosinophil counts or serum periostin levels compared to placebo in patients with asthma.
Why the study?
The study was conducted to investigate the effect of atorvastatin on serum periostin level and blood eosinophil count in patients with asthma.
Does atorvastatin reduce blood eosinophil count and serum periostin levels in patients with asthma?
RCT (n=80)
Triple-blind
Simple randomization
Yes
Does atorvastatin reduce blood eosinophil count and serum periostin levels in patients with asthma?
Atorvastatin 40 mg daily for 8 weeks did not significantly change spirometric parameters or inflammatory markers (blood eosinophils, serum periostin) in patients with asthma compared to placebo.
Answers are grounded in this paper and cite their sources.
Atorvastatin does not alter spirometry or eosinophilic markers in asthma; confirms lack of anti-inflammatory effect in this RCT.
OBJECTIVE: To investigate the effect of atorvastatin on serum periostin level and blood eosinophil count in patients with asthma. METHODS: Patients diagnosed with asthma were enrolled and randomised into an intervention or placebo group, to receive 40 mg atorvastatin or similar placebo, daily, for 8 weeks. Spirometry was performed at baseline, and at the end of weeks 4 and 8; patients also provided blood samples and completed an asthma control test (ACT) at baseline and at the end of week 8. Primary study outcomes were blood eosinophil count and serum periostin levels. RESULTS: Eighty patients completed the study (40 per group). Mean ACT scores were similar between the intervention and placebo groups at baseline (17.95 ± 3.75 versus 17.98 ± 3.77, respectively), and improved in the intervention group (19.88 ± 3.28), but remained unchanged in the placebo group (18.6 ± 3.26) during the treatment period. No statistically significant differences in spirometric changes, blood eosinophil count or serum periostin levels were observed between the groups during the treatment period. CONCLUSION: Spirometric parameters and inflammatory markers did not change significantly in response to atorvastatin treatment, and did not differ between the placebo and intervention groups.
No takes yet. Share an insight, caveat, or question.
Mehrabi et al. (2021) conducted an RCT in Asthma (n=80). Atorvastatin vs. Placebo was evaluated on Blood eosinophil count (%) at 8 weeks (p=>0.05). Atorvastatin daily for 8 weeks did not change blood eosinophil counts or serum periostin levels compared to placebo in patients with asthma.
Synapse has enriched 10 related papers. Consider them for comparative context: